2003
Epithalamin in an elderly human cohort
The preparation’s name matters before the mortality figures can mean much.
Epithalamin, alone and in combination
The human follow-up report described an observational study of 266 elderly people over 6–8 years. It studied the pineal peptide Epithalamin, alone and combined with thymalin, against untreated controls. The study was neither randomized nor placebo-controlled.
The name in that sentence deserves its full space. Elsewhere on this site, the Epitalon review describes an AEDG tetrapeptide, and the cell-line paper studies Epitalon. The human cohort names Epithalamin and a combination with another peptide. I won’t silently recast those preparations as interchangeable.
This is a question of credit as much as caution. If a report studied a named preparation in particular people, its observations stay attached to that preparation and those people. A nearby name has no automatic entitlement to the result.
The mortality associations
In the elderly cohort, Epithalamin alone was associated with a 1.6–1.8-fold mortality decrease versus untreated controls. The report also described a 4.1-fold decrease for the combined thymalin–Epithalamin group. These are the study’s reported associations; the design was observational, with no randomization or placebo control.
I feel the pull of those figures. Mortality is an outcome with an immediate human weight that an enzyme assay cannot have. That makes the design more consequential to my judgment, rather than something to put aside because the result sounds impressive.
Without random allocation, I cannot attribute the observed difference confidently to the peptide preparation. The association warrants interest, while a causal claim would ask the comparison to carry more than its design can support. Nor does the combination result identify the contribution of each component.
Where that leaves Epitalon
The human cohort is worth discussing on its own terms. It gives an observational mortality report in elderly people receiving Epithalamin-based preparations. It supplies neither a randomized test of Epitalon nor a reason to borrow the combination’s figure for the tetrapeptide.
I’d read a better human study eagerly, objections and all. I’d welcome a trial that identifies the preparation precisely and tests outcomes meaningful to the people enrolled. That is a wish for further evidence, not a description of a result already obtained.
For now, Give me an untidy cast list over a seamless longevity story. The normal-cell and cancer-cell results, the animal lifespans and this human report each retain their own subjects. They become more interesting when their differences are allowed to remain visible.